Search Results

2006 ; 106 : 2258 – 2266 . 3 Lyman GH Dale DC Crawford J . Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices . J Clin Oncol 2003 ; 21 : 4524 – 4531 . 4

to improve patient outcomes. 22 Relative dose intensity (RDI), or the ratio of delivered dose intensity to standard or planned dose intensity, is a summary measure that is commonly used to describe dose delays and/or reductions that occur within a

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

Crawford J Dale DC Lyman GH . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 7 Dale DC McCarter GC Crawford J . Myelotoxicity and dose intensity of chemotherapy

complications, including febrile neutropenia, infection, and infection-related mortality, in patients undergoing cancer chemotherapy, while enabling an increase in delivered chemotherapy dose intensity. 1 , 2 Clinical practice guidelines from NCCN, ASCO, and

STRENGTH pathway, a retrospective QI analysis assessed an equal number of patients in the pre-STRENGTH and STRENGTH group for chemotherapy and radiation therapy dose intensities, as well as treatment outcomes. Results: During the pre-STRENGTH period

References 1. Phillips LS Branch WT Cook CB . Clinical inertia . Ann Int Med 2001 ; 135 : 825 – 834 . 2. Shayne M Crawford J Dale DC . Predictors of reduced dose intensity in patients with early-stage breast cancer

. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 3. Hryniuk W Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer . J Clin Oncol

://www.nccn.org . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy

, facilitating the safe delivery of planned chemotherapy dose intensity on schedule. Guidelines from NCCN and ASCO on the use of MGFs have recently been updated. 7 , 8 When selecting patients for primary prophylaxis with G-CSF, current guidelines recognize the